ARL14EPL Inhibitors
ARL14EPL inhibitors, which indirectly disrupt the functional activity of ARL14EPL, include compounds that modulate specific signaling pathways and biological processes such as GTPase signaling, vesicular trafficking, and cytoskeletal organization. These compounds act by inhibiting enzymes and factors that indirectly influence the activity of ARL14EPL. For instance, interventions targeting phosphoinositide 3-kinase impact downstream AKT signaling, which is essential for GTPase activity and membrane dynamics that ARL14EPL is associated with. Inhibition of phospholipase C prevents the formation of second messengers from PIP2, consequently altering membrane trafficking, where ARL14EPL is implicated. Additionally, by affecting protein kinase C, the phosphorylation state of proteins involved in cytoskeletal dynamics and membrane trafficking may be altered, thus influencing ARL14EPL's role in these cellular processes.
Furthermore, compounds that inhibit specific GTPases such as Cdc42 or Rac1, or their associated GEFs, can impact the organization of the actin cytoskeleton and membrane trafficking, processes that ARL14EPL may regulate, thereby indirectly inhibiting its function. Toxins that modify Rho GTPases could also disrupt the cytoskeleton and vesicle trafficking, leading to the functional inhibition of ARL14EPL. The use of a ROCK inhibitor might affect actin dynamics and consequently the processes involving ARL14EPL. Similarly, by impeding actin polymerization or dynamin-mediated endocytosis, the inhibitors could influence cytoskeletal reorganization and vesicle trafficking, thus indirectly inhibiting the function of ARL14EPL.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that disrupts the PI3K/AKT signaling pathway, resulting in reduced downstream signaling that could otherwise affect the activity of ARL14EPL by altering its GTPase activity or membrane association. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factors (ARFs) that blocks the exchange of GDP for GTP, which may indirectly inhibit ARL14EPL's function by disrupting ARF-related GTPase functions and vesicular trafficking processes. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
A protein kinase C (PKC) inhibitor that can modify the phosphorylation state of proteins involved in membrane trafficking and cytoskeletal dynamics, possibly influencing ARL14EPL's role in these cellular processes. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
A selective inhibitor of Cdc42 GTPase, which by inhibiting Cdc42 could indirectly affect the actin cytoskeleton organization and membrane trafficking, thus potentially influencing the function of ARL14EPL in cellular processes. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $273.00 | 6 | |
An inhibitor of cytohesins, which are guanine nucleotide exchange factors (GEFs) for ARF GTPases, thereby potentially diminishing ARL14EPL-mediated GTPase signaling by reducing active ARF GTPases in the cell. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
An inhibitor of Rac1 GTPase interaction with GEFs, potentially affecting cytoskeletal reorganizations and membrane trafficking where ARL14EPL might play a role, consequently leading to an indirect inhibition of its function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A Rho-associated protein kinase (ROCK) inhibitor that may impact actin cytoskeleton organization and membrane trafficking, potentially affecting processes where ARL14EPL is implicated, and thus indirectly inhibiting its function. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $229.00 | 29 | |
An actin polymerization inhibitor that disrupts the actin cytoskeleton, which could in turn influence cellular processes involving ARL14EPL, leading to its functional inhibition through impaired cytoskeletal dynamics. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
A dynamin inhibitor that blocks GTPase activity of dynamin, leading to the disruption of clathrin-mediated endocytosis and vesicle trafficking, processes that ARL14EPL may be involved in, thus potentially inhibiting its function. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
A Cdc42 GTPase inhibitor that disrupts the Cdc42-PAK1 interaction, potentially affecting actin cytoskeleton reorganization and vesicle trafficking, which are processes that could be influenced by ARL14EPL, leading to its functional inhibition. | ||||||